European Commission clears BD acquisition of CareFusion
The proposed acquisition has now received all necessary regulatory approvals.
The proposed acquisition, which has been approved by CareFusion shareholders, remains subject to customary closing conditions. BD and CareFusion currently expect the proposed acquisition to close on March 17, 2015.
In October 2014, BD and CareFusion announced a definitive agreement under which BD will acquire CareFusion for $58 per share in cash and stock, or a total of $12.2 billion, to create a global leader in medication management and patient safety solutions.
The agreement has been unanimously approved by the Boards of both companies.
The combination of the two companies’ complementary product portfolios will offer integrated medication management solutions and smart devices, from drug preparation in the pharmacy, to dispensing on the hospital floor, administration to the patient, and subsequent monitoring. ■